Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Lilly invests $3 billion to expand Wisconsin plant
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products. Lilly said Thursday it will expand a Kenosha County,
Eli Lilly CEO says Mounjaro maker may consider other Wisconsin sites for new plants
Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin sites for new plants beyond a $3 billion project the company announced in Kenosha County, the company’s CEO told the Milwaukee Business Journal.
Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, Wisconsin earlier this year, as it scrambles to meet soaring demand for its weight-loss and diabetes drugs.
Lilly’s Zepbound wins weight loss duel with Novo’s Wegovy
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Eli Lilly’s Weight-Loss Drug Zepbound More Effective than Novo’s Wegovy, Study Shows
New data indicating Eli Lilly’s obesity shot Zepbound works better than Novo Nordisk’s Wegovy could add fuel to Lilly’s new efforts to market the drug as shortages ease.Recent months have brought new questions about whether the sky-high expectations for Zepbound’s sales—which have sent Lilly’s share price up more than 230% over the past three years—may be overly optimistic.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
14h
Ozempic cuts drinking, Zepbound beats Wegovy, and a blood test detects 50 cancers: Pharma news roundup
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
1d
on MSN
Lilly's Zepbound will first be given in the UK to those with 'highest clinical need'
The initial rollout of Eli Lilly's weight loss drug Zepbound in the UK will first go to those with the great clinical need ...
1d
on MSN
Lilly to Boost Obesity Drug Supply With $3 Billion Expansion
Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Manslaughter dropped
US adds 227,000 jobs
Family awarded $310 million
Taking extended leave
Chinese vessel hijacked
Climbers feared dead
Havana syndrome report
Drops bid for third term
Federal fraud charges arrest
Use of race in admissions OK'd
Biden considers pardons
Several prisons to be closed
Trump shows public support
‘One Life to Live’ star dies
Wild bird lays egg at 74
Promotes trade w/ Mexico
Recalls 300K+ Ram trucks
AI bias meter coming
Romanian election annulled
Oven gloves recalled
Scott tapped to lead CBP
Hit six months in space
Massive fire in Baltimore
Sacks to lead AI, crypto
White Sox legend dies
Ethics report release blocked
Pledges hit $100 billion
Blackhawks fire coach
Syrian rebels advance
Judge rejects plea deal
Messi wins MLS MVP award
Iran: Space launch successful
'Patriot of the Year' award
Moon missions delayed
Appeals court upholds ban
NBA returning to China
Joins X Games as CEO
Related topics
Mounjaro
Wegovy
Novo Nordisk
Amgen
Glucagon-like peptide-1
Feedback